Zakharia, Yousef http://orcid.org/0000-0001-9480-2626
Singer, Eric A.
Acharyya, Satwik
Garje, Rohan
Joshi, Monika
Peace, David http://orcid.org/0000-0002-9403-760X
Baladandayuthapani, Veera
Majumdar, Annesha
Li, Xiong
Lalancette, Claudia http://orcid.org/0000-0002-6854-4034
Kryczek, Ilona http://orcid.org/0000-0002-3130-2533
Zou, Weiping http://orcid.org/0000-0001-7952-3549
Alva, Ajjai
Article History
Received: 30 September 2022
Accepted: 18 January 2024
First Online: 1 February 2024
Competing interests
: Y.Z.: advisory boards: Bristol Myers Squibb, Amgen, Roche Diagnostics, Novartis, Janssen, Eisai, Exelixis, Castle Bioscience, Genzyme Corporation, Astrazeneca, Array, Bayer, Pfizer, Clovis, EMD Serono, Myovant. Grant/research support from: institutional clinical trial support from NewLinkGenetics, Pfizer, Exelixis, Eisai. Data safety and monitoring committee: Janssen Research and Development. Consultant honorarium: Pfizer, Novartis. E.S.: institutional research funding: Medivation/Astellas. Advisory boards: Merck, Johnson & Johnson, Vyriad. Data safety monitoring board: Aura Biosciences. M.J.: institutional research funding: AstraZeneca. Advisory boards: Seagen, Gilead. Travel and accommodation: DAVA Oncology. Mentor on diversity grant: Bristol Myers Squibb. S.A., R.H., D.P., V.B., A.M., XL, C.L., I.K., W.Z., A.A.: declare no competing interest.